Photodermatology, photoimmunology & photomedicine最新文献

{"title":"UV Protection Habits and Preferences in Patients With Distinct Cutaneous Immune-Mediated Inflammatory Diseases.","authors":"Zita Álvarez-Bobillo, Iranzu Barandika-Urrutia, Tamara Gracia-Cazaña, Yolanda Gilaberte-Calzada","doi":"10.1111/phpp.70084","DOIUrl":"10.1111/phpp.70084","url":null,"abstract":"<p><strong>Background: </strong>Achieving adequate UV protection can be particularly challenging in patients with cutaneous immune-mediated inflammatory dermatoses (IMIDs), owing to the clinical characteristics and quality-of-life impact of these diseases.</p><p><strong>Objectives: </strong>To compare the UV protection habits and preferences of patients with cutaneous IMIDs, specifically considering expert recommendations for these diseases.</p><p><strong>Methods: </strong>This pilot cross-sectional, observational and analytical cohort study recruited 120 participants (78 female, 42 male; mean age, 40.8 ± 15.39 years): 20 cases for each IMID (vitiligo, atopic dermatitis, alopecia areata, psoriasis and hidradenitis suppurativa) and 20 healthy controls. Study variables included eye and hair color, BMI, phototype, clinical severity scales for each IMID, the Dermatology Life Quality Index (DLQI) score and a study-specific questionnaire on photoprotection preferences.</p><p><strong>Results: </strong>Daily photoprotection was reported by 40% of participants, with highest adherence (55%) in vitiligo patients. Hat use was generally low (24.17%), except among alopecia areata patients (40%). Overall, 63.3% of participants reported no sunburn in the last year, and 95% used an SPF > 15. Cream was the most commonly used SPF format, followed by spray. Oral photoprotection was known by 33.3% of participants, with highest use reported by vitiligo patients (45%). Compliance with UV protection recommendations for their specific disease was highest among vitiligo patients (70%), but did not exceed 10% for any other IMID.</p><p><strong>Conclusions: </strong>Educating patients with cutaneous IMIDs about appropriate UV protection, tailored to their specific skin disorder, treatments and preferences, is crucial to improve compliance and disease control.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 2","pages":"e70084"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12989706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Clinical Trial: The Comparative Therapeutic Efficacy of Tap Water-UVA, Saltwater-UVA, and Conventional Bath PUVA in Palmoplantar Pustulosis.","authors":"Hilayda Karakök Kışla, Mustafa Gündoğdu, Ayşenur Botsalı, İrem Kar, Nihal Kundakçı, Cengizhan Erdem","doi":"10.1111/phpp.70081","DOIUrl":"10.1111/phpp.70081","url":null,"abstract":"<p><strong>Background & purpose: </strong>Bath or oral PUVA is a key treatment modality for palmoplantar pustulosis (PPP), whereas topical PUVA and UVB have proven ineffective. Immersion in water prior to UVA may represent a therapeutic option.</p><p><strong>Method: </strong>This study was a prospective, open label, three-arm parallel-group randomized controlled trial conducted from 2014 to 2017. The study was conducted in Ankara University Medical School Department of Dermatology and Venereology. The ethical committee approval was granted (07.10.2013- no 15-585-13) and the trial registration number was NCT06458868. All participants had a biopsy with a confirmed diagnosis of PPP. The primary endpoint of the study was defined as having achieved a PPASI50 response at week 36. Out of 114 eligible patients, 68 patients were enrolled in the study. Randomization was performed using a computer program (clinstat). All arms received UVA irradiation for 36 sessions starting at 0.25 J/cm² with incremental increases. Bath PUVA arm: Local baths with water containing 0.5 mg methoxypsoralen per litre at 37°C for 20 min prior to phototherapy. Tap Water (TW) Group received local baths in tap water, Saltwater (SW) Group received local baths in 25% w/v saline solution, both at 37°C for 20 min prior to phototherapy.</p><p><strong>Results: </strong>Out of 68 enrolled participants, 50 completed the study (F/M: 43/7, age: 47.8 ± 10.3 years). In the intention to treat set, PPASI-50 response rates were 38.5%, 57.1%, and 71.4% in the TW, SW, and bath-PUVA groups (p = 0.085). In the per protocol set, corresponding rates were 52.6%, 85.7%, and 88.2% (p = 0.031).</p><p><strong>Conclusions: </strong>Immersion in water or saltwater prior to UVA without psoralens may provide a therapeutic effect.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 2","pages":"e70081"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Predictors of Relapse-Free Duration After Narrowband UVB in Pediatric Psoriasis: A Multicenter Study.","authors":"Berna Solak, Burhan Engin, Zeynep Güngör, Ömer Faruk Tolun, Zafer Türkoğlu, Dilay Baştuğ, Harbiye Dilek Canat, Tubanur Çetinarslan, Aylin Türel Ermertcan, Selen Gezmen, Özge Zorlu, Hülya Albayrak, Nazlı Caf, Ümit Türsen","doi":"10.1111/phpp.70076","DOIUrl":"10.1111/phpp.70076","url":null,"abstract":"<p><strong>Background: </strong>Narrowband ultraviolet B (NB-UVB) phototherapy is a well-established, safe, and effective treatment for pediatric psoriasis; however, relapse after therapy remains a major challenge. Data regarding prognostic factors influencing remission durability in children are limited.</p><p><strong>Objectives: </strong>To evaluate treatment response, relapse patterns, and predictors of relapse-free duration in pediatric psoriasis patients treated with NB-UVB phototherapy, with a particular focus on concomitant topical corticosteroid and calcipotriol use, and clinical features such as nail involvement.</p><p><strong>Methods: </strong>This multicenter retrospective study included 114 pediatric psoriasis patients treated with NB-UVB across six tertiary dermatology centers in Türkiye. Treatment response was defined as ≥ 75% improvement in the Psoriasis Area and Severity Index (PASI75). Relapse was defined as clinically significant recurrence requiring renewed NB-UVB or systemic therapy within 6 months after treatment completion. Multivariable linear regression identified independent predictors of relapse-free duration.</p><p><strong>Results: </strong>Of 114 patients (mean age 12.2 ± 3.6 years; 52.6% male), 65.8% achieved PASI75 and 42.1% PASI90. Responders received significantly higher cumulative doses and more sessions than nonresponders (p < 0.001). Relapse occurred in 24.0% of responders within 6 months. In multivariate analysis, concomitant topical corticosteroid use independently predicted longer relapse-free duration (β = 0.578, p = 0.001), whereas nail involvement predicted shorter remission (β = -0.520, p = 0.002). Topical calcipotriol and disease subtype were not significant predictors. NB-UVB was well tolerated, with mild erythema and pruritus as the most frequent adverse events (16.7%).</p><p><strong>Conclusion: </strong>NB-UVB phototherapy provides high efficacy and an acceptable safety profile in pediatric psoriasis. Concomitant topical corticosteroid use may prolong remission, while nail involvement identifies patients at higher relapse risk, supporting closer monitoring and individualized follow-up and maintenance strategies.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 2","pages":"e70076"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146181790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apremilast, Methotrexate and NB-UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison.","authors":"Alessia Balestrino, Serena Lembo, Raffaella Manzo, Maria Grazia Battipaglia, Annunziata Nigro, Annunziata Raimondo","doi":"10.1111/phpp.70066","DOIUrl":"10.1111/phpp.70066","url":null,"abstract":"<p><strong>Background: </strong>Selecting the most appropriate therapy for psoriasis remains challenging due to variability in disease severity and individual patient factors. Among non-biological treatments, methotrexate (MTX), apremilast (APRE), and narrowband UVB (NB-UVB) phototherapy are widely utilized.</p><p><strong>Objective: </strong>To compare, under real-world conditions, the clinical efficacy, quality of life, patient satisfaction, and immunomodulatory effects of APRE, MTX, and NB-UVB in moderate-to-severe plaque psoriasis over 16 weeks.</p><p><strong>Methods: </strong>This pilot prospective observational cohort study included 37 patients treated independently with APRE (n = 13), MTX (n = 15), or NB-UVB (n = 9). Clinical outcomes were assessed using PASI, BSA, PGA, DLQI scores, and the TSQM-9 questionnaire. Systemic and local inflammation were assessed by multiplex cytokine assays and RT-PCR in vivo and in vitro.</p><p><strong>Results: </strong>By Week 16, significant improvements were observed in PASI, DLQI, and PGA scores across all groups, with no statistically significant differences in efficacy between treatments. A trend toward a greater response was observed for both MTX and APRE. APRE treatment demonstrated a tendency for more pronounced modulation of pro-inflammatory cytokines compared to both MTX and NB-UVB. NB-UVB increased the anti-inflammatory IL-10. Combination therapy with NB-UVB and APRE further increased IL-10 levels and reduced IL-33 in HaCaT cells, suggesting synergistic immunomodulatory effects; however, the clinical relevance of these in vitro findings remains unproven and requires further investigation.</p><p><strong>Conclusion: </strong>APRE, MTX, and NB-UVB each improved clinical outcomes with comparable overall efficacy and good tolerability in this pilot cohort. Each therapeutic regime showed distinct immunomodulatory profiles with good tolerability. Personalized treatment strategies, including potential combinations, may optimize outcomes for patients with moderate-to-severe psoriasis.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 1","pages":"e70066"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"308-nm Excimer Light for Inflammatory Acne in Pregnancy: A Prospective Pilot Study.","authors":"Mahmoud A Rageh, Amr Mohammad Ammar, Sara M Mohy, Muhammad Mohsen, Kamal Rageh, Abeer Attia Tawfik","doi":"10.1111/phpp.70072","DOIUrl":"10.1111/phpp.70072","url":null,"abstract":"<p><strong>Background/purpose: </strong>Concerns about fetal safety limit acne treatments during pregnancy. The 308-nm excimer light offers targeted UVB exposure to lesions with less impact on healthy skin compared to whole-body NB-UVB. We assessed the efficacy and safety of lesion-directed excimer light for inflammatory acne in pregnancy, including folate monitoring and obstetric outcomes.</p><p><strong>Methods: </strong>This single-center, single-arm pilot study was conducted in 13 pregnant women with inflammatory acne in the second trimester. Lesion-directed 308-nm excimer light was delivered to facial lesions twice weekly for 8 weeks with erythema-guided escalation; serum folate was monitored, and obstetric outcomes were captured prospectively. For assessment of improvement, the Investigator's Global Assessment (IGA) and the Dermatology Life Quality Index (DLQI) were applied. Analyses emphasized estimation with 95% CIs; exploratory patient-reported/assessor correlations used Spearman's ρ with exact p-values.</p><p><strong>Results: </strong>Both inflammatory and non-inflammatory lesions improved; the primary endpoint showed a 48.3% mean reduction in inflammatory lesions at Week 8, 5/13 achieved a ≥ 2-grade IGA improvement, and mean DLQI improved by 5.9 points. Serum folate remained within the reference range, and obstetric outcomes were reassuring.</p><p><strong>Conclusion: </strong>Excimer light was associated with clinically meaningful reductions in inflammatory acne lesions with reassuring safety signals and obstetric outcomes. It may be a pregnancy-compatible option when other therapies are limited and merits evaluation in controlled trials.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 1","pages":"e70072"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145857490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitiligo in Xeroderma Pigmentosum: A Protective Phenomenon Against Skin Cancer?","authors":"Ahmet Taha Aydemir, Sule Altiner, Bengu Nisa Akay","doi":"10.1111/phpp.70073","DOIUrl":"https://doi.org/10.1111/phpp.70073","url":null,"abstract":"","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 1","pages":"e70073"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145857517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Urea 10% Promote Photosensitizer Uptake Before MAL-PDT for the Treatment of Facial Actinic Keratoses? Results of a Randomized Clinical Trial.","authors":"Grazia Linda Artelli, Isacco Cattaneo, Luca Rubelli, Cesare Ariasi, Stefano Bighetti, Cesare Tomasi, Gaetano Licata, Simone Soglia, Piergiacomo Calzavara-Pinton, Mariachiara Arisi","doi":"10.1111/phpp.70058","DOIUrl":"10.1111/phpp.70058","url":null,"abstract":"<p><strong>Background: </strong>Actinic keratoses (AKs) are precancerous lesions that may progress to squamous cell carcinoma (SCC). Photodynamic therapy (PDT) with methyl aminolevulinate (MAL) is an established treatment, often preceded by mechanical curettage to enhance photosensitizer penetration. However, curettage is associated with pain and discomfort, necessitating alternative pretreatment strategies, also applicable in daylight PDT.</p><p><strong>Methods: </strong>Thirty-six patients with symmetrical facial AKs were randomized to receive MAL-PDT on two contralateral areas: one pretreated with a 10% urea-based keratolytic compound (UBC) for 14 days and the other untreated (control). Protoporphyrin IX (PpIX) fluorescence, clinical outcomes, cosmetic results, and patient satisfaction were assessed. Statistical analyses included the Wilcoxon, Mann-Whitney, and chi-squared tests (p ≤ 0.05).</p><p><strong>Results: </strong>The urea-pretreated group showed significantly higher fluorescence intensity (median: 7 [5-9]) vs. controls (median: 5 [3-6]; **p < 0.0001**), indicating improved MAL penetration. Both groups had significant AK reductions (**p = 0.02**). The reduction in Olsen grade I AKs was greater with UBC (**p < 0.0001**), while no significant differences were observed for grade II lesions. Tolerability and patient satisfaction were high, with no significant differences in pain scores, local skin reactions, or cosmetic outcomes.</p><p><strong>Conclusions: </strong>Pretreatment with a 10% UBC enhances PpIX fluorescence and improves efficacy in grade I AKs when compared to no pretreatment. Thus, it provides a non-invasive pretreatment option with good efficacy in thin AKs, along with good patient satisfaction and safety.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"41 6","pages":"e70058"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12585119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laser Photobiomodulation of Human Dermal Fibroblasts Combined With Plasma Rich in Growth Factors and Platelet-Rich Plasma: A Comparative In Vitro Analysis.","authors":"Sameerah Hasan Abdullah, Manijhe Mokhtari-Dizaji, Zeinab Hormozi-Moghaddam, Mohsen Bakhshandeh, Mohammad Ali Nilforoshzadeh","doi":"10.1111/phpp.70063","DOIUrl":"10.1111/phpp.70063","url":null,"abstract":"<p><strong>Background/purpose: </strong>Platelet-rich plasma (PRP) and plasma rich in growth factors (PRGF) are autologous preparations widely applied in regenerative medicine because of their potential to enhance tissue repair and cellular activity. Low-level laser therapy (LLLT) has also been reported to promote fibroblast proliferation and mitochondrial activity. This study aimed to investigate the combined effects of PRP, PRGF, and LLLT on human dermal fibroblasts (HDFCs).</p><p><strong>Methods: </strong>HDFCs were cultured and treated with varying concentrations of PRP and PRGF. Cells were subsequently exposed to a gallium-aluminum-arsenide (GaAlAs) laser at 830 nm, 10 mW, continuous mode, for 90 s, 3 min, or 6 min. Proliferation, metabolic activity, and oxidative stress were evaluated using MTT, ATP, and ROS assays at 24 h and 48 h.</p><p><strong>Results: </strong>A significant increase (p < 0.001) in proliferation and ATP production was observed in the PRP 30% and PRGF 60% groups after 90 s of LLLT. MTT values were 1.17 ± 0.00 and 1.39 ± 0.05 at 24 h, and 1.40 ± 0.04 and 1.62 ± 0.01 at 48 h, respectively. ATP levels reached 6710.33 ± 59.72 and 18,709 ± 535.29 RLU at 24 h, and 8202 ± 333.39 and 22,272 ± 839.64 RLU at 48 h, compared with control (1005 ± 52.92 RLU). No significant differences in ROS activity were detected among most groups, although PRGF 70% showed elevated ROS with and without laser irradiation.</p><p><strong>Conclusion: </strong>PRP and PRGF synergistically enhanced fibroblast proliferation and metabolism when combined with LLLT. PRGF consistently demonstrated greater effects compared with PRP. Optimal stimulation was achieved with 90 s of LLLT at 10 mW (3.78 J/cm²) combined with 30% PRP or 60% PRGF.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"41 6","pages":"e70063"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Meta-Analysis of the Oxidative and Inflammatory Reactions to the Type and Duration of Phototherapy in Neonates With Jaundice.","authors":"Xiaoyuan Zhang, Hui Zhang, Chao Gao, Hongli Chen, Lei Zhang","doi":"10.1111/phpp.70056","DOIUrl":"10.1111/phpp.70056","url":null,"abstract":"<p><strong>Background: </strong>Phototherapy reduces serum free bilirubin levels but can also cause various short- and long-term side effects. This meta-analysis examined the potential relationship between phototherapy duration and type, as well as oxidative and inflammatory reactions in newborns with hyperbilirubinemia.</p><p><strong>Methods: </strong>We searched PubMed, the Cochrane Library, Web of Science, and Embase for observational studies published before December 31, 2023. The Quality in Prognostic Studies (QUIPS) tool was used to evaluate the risk of bias. The intervention included the durations (1.5, 12, 24, 36, 48, 72, and > 90 h) and types (light-emitting diode (LED), conventional, and intensive) of phototherapy.</p><p><strong>Results: </strong>A total of 24 observational studies with 1230 newborns were included in the study. Phototherapy increased the increased oxidative stability index. The oxidative indexes decreased after 1.5 or 90 h of phototherapy but increased after 24 or 48 h. Phototherapy increased nitric oxide levels but was associated with reduced total antioxidant capacity and glutathione. Conventional phototherapy reduced antioxidant indices, whereas LED was associated with increased oxidative indices. After 36 h, phototherapy reduced hematocrit levels. Phototherapy increased the secretion of inflammatory mediators by peripheral blood mononuclear cells after 24 h. In addition, conventional phototherapy increased levels of inflammatory mediators in the serum of infants after 72 h.</p><p><strong>Conclusion: </strong>Side effects of phototherapy, such as altered oxidant/antioxidant status and inflammatory reactions, may vary depending on the type of phototherapy used. However, no clear pattern was observed in the alterations in these oxidative/inflammatory markers as a function of the duration of phototherapy.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"41 6","pages":"e70056"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PINGing Sunshine: A Review of the Evidence for Adding Non-Filtering Photoprotective Ingredients to Sunscreens.","authors":"Jean Krutmann, Anthony Brown, Thierry Passeron, Corinne Granger, Yolanda Gilaberte, Carles Trullas, Jaime Piquero-Casals, Giovanni Leone, Sergio Schalka, Henry W Lim","doi":"10.1111/phpp.70062","DOIUrl":"10.1111/phpp.70062","url":null,"abstract":"<p><strong>Background: </strong>Photoprotective INGredients (PINGs) are non-filtering agents that enhance the skin's intrinsic defenses against solar radiation. Acting through antioxidant, DNA repair, immunomodulatory, anti-inflammatory, and pigmentation-regulating mechanisms, PINGs may prevent or repair photodamage. When incorporated into sunscreens, they offer protection beyond ultraviolet (UV) filters. This strategy of biological photoprotection could address key limitations of traditional sunscreens and reduce dependence on high UV filter concentrations.</p><p><strong>Methods: </strong>We conducted a focused literature review based on our prior evidence-based classification of over 1700 topical PINGs. We selected ingredients with the strongest clinical and mechanistic support and assessed their biological activity, formulation compatibility, and relevance to key endpoints such as erythema, pigmentation, photoaging, and immunosuppression.</p><p><strong>Results: </strong>Top-ranked PINGs, including L-ascorbic acid, tocopherol, photolyase, and nicotinamide, demonstrated efficacy across multiple photodamage endpoints. Antioxidants like L-ascorbic acid and tocopherol enhanced protection against UVR and IR-A-induced oxidative stress. DNA repair enzymes, such as photolyase, reduced cyclobutane pyrimidine dimer formation and supported immune function. Nicotinamide improved DNA repair and prevented UV-induced immunosuppression. Pigmentation modulators such as p-coumaric acid and isobutylamido thiazolyl resorcinol showed benefits in darker phototypes.</p><p><strong>Conclusions: </strong>Fewer than 2% of candidate PINGs are clinically validated, and only 18 are approved for use in sunscreens. Protection against visible and infrared radiation remains largely underexplored. Standardized testing and additional clinical trials are needed to advance PINGs as effective components of next-generation sunscreens.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"41 6","pages":"e70062"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12568756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145392165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}